- Citations, last 5 years
- 453
- Works, last 5 years
- 52
- h-index
- 76
- Scientists listed
- 8
- Grants since 2016
- 17
Grants received
2024–2025 · research · R43
Developing a novel epigenetic regulator as a treatment for opioid use disorder
Thomas Kim · EpiVax (United States) · funded by National Institutes of Health
2024–2025 · research · R43
Developing a novel epigenetic regulator as a treatment for cocaine use disorder
Thomas Kim · EpiVax (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities
Kirk Donald Haltaufderhyde · EpiVax (United States) · funded by National Institutes of Health
2023–2024 · research · R43
PA21259, SBIR, Phase I, Improving T cell Responses in Vaccines: Prediction and Validation Using Existing Databases, Immunoinformatics and In Vitro Assays
Mayara Grizotte-Lake · EpiVax (United States) · funded by Centers for Disease Control and Prevention
2022–2023 · research · R41
ACSS2 inhibition in treating Alcohol Abuse
Howard C. Becker · EpiVax (United States) · funded by National Institutes of Health
2022–2025 · cooperative agreement · U01
ISPRI-HCP: CHO protein impurity immunogenicity risk prediction for improving biosimilar product development and assessing product interchangeability
Anne Searls Degroot · EpiVax (United States) · funded by U.S. Food and Drug Administration
2018–2020 · research · R43
GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health
2018–2020 · research · R43
GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health
2017–2024 · research · R01
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health
2017–2020 · research · R43
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health
2017–2022 · research · R01
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health
2017–2022 · research · R01
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health
2017–2022 · research · R01
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health
2017–2022 · research · R01
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health
2016–2020 · research · R43
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza
Anne Searls Degroot · EpiVax (United States) · funded by National Institutes of Health